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Abstract Four main DNA mismatch repair (MMR) genes
have been identified, MLH1, MSH2, MSH6, and PMS2,
which when mutated cause susceptibility to Lynch syn-
drome (LS). LS is one of the most prevalent hereditary
cancer syndromes in man and accounts for 1–3 % of uns-
elected colorectal carcinomas and some 15 % of those with
microsatellite instability and/or absent MMR protein. The
International Society for Gastrointestinal Hereditary
Tumours (InSiGHT) maintains a database for LS-associ-
ated mutations since 1996. The database was recently
reorganized to efficiently gather published and unpublished
data and to classify the variants according to a five-tiered
scheme linked to clinical recommendations. This review
provides an update of germline mutations causing suscep-
tibility to LS based on information available in the
InSiGHT database and the latest literature. MMR gene
mutation profiles, correlations between genotype and phe-
notype, and possible mechanisms leading to the charac-
teristic spectrum of tumors in LS are discussed in light of
the different functions of MMR proteins, many of which
directly serve cancer avoidance.
Keywords Lynch syndrome  Mutation  Epimutation 
Tumor spectrum  DNA mismatch repair
DNA mismatch repair genes: shared
and specialized functions
Functional DNA mismatch repair (MMR) is vital for basic
biology and cancer avoidance. The main function of MMR
proteins is to maintain genomic stability by correcting
single-base mismatches and insertion/deletion loops (IDL)
that may arise during replication [1]. Malfunction of MMR
results in a mutator phenotype and microsatellite instability
(MSI) characteristic of most tumors from Lynch syndrome
(LS) and some 15 % of sporadic tumors [2]. MMR proteins
also recognize diverse types of endogenous and exogenous
damage, such as that induced by oxidation [3] or alkylation
[4], and correct the lesions, or if this is not possible, signal
DNA damage to cell cycle arrest or apoptosis. MMR pro-
teins regulate genetic recombination by correcting mis-
matches that may occur in recombination during meiosis
and by suppressing recombination between homeologous
(=related but non-identical) sequences during mitosis [5].
Unexpectedly, the MMR system can also promote muta-
tions when needed. For example, the MMR proteins MSH4
and MSH5 facilitate meiotic crossover between homolo-
gous chromosomes [6]. Additionally, MMR proteins pro-
mote somatic hypermutation and class switch of antibody
genes [7].
In humans, five MutS homologues (MSH2, MSH6,
MSH3, MSH4, and MSH5) and four MutL homologues
(MLH1, PMS2, PMS1, and MLH3) have been identified
which can form heterodimers in different combinations [8–
10] (Fig. 1). The main mismatch-binding factor in humans
is hMutSa, consisting of MSH2 and MSH6, which recog-
nizes single-base mispairs and IDLs. Another mismatch-
binding heterodimer is hMutSb, formed by MSH2 and
MSH3, which mainly acts on IDLs. Upon mismatch
binding, the hMutS complex undergoes an ATP-driven
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conformational change into a sliding clamp and a hMutL
heterodimer is recruited. The main hMutL complex is
hMutLa, consisting of MLH1 and PMS2 and participating
in the repair of single-base mismatches and IDLs. Alter-
native hMutL heterodimers are hMutLc, composed of
MLH1 and MLH3, which may predominantly contribute to
IDL repair, and hMutLb (MLH1 and PMS1), which does
not seem to participate in MMR. When the hMutS-hMutL
complex encounters a strand discontinuity, an excision
machinery is recruited, the mismatch containing fragment
is degraded, and a new strand synthesized [7, 9].
Substrate specificities of the individual MMR proteins
are reflected in the different MSI phenotypes observed in
tumors from LS patients. MSH2 and MLH1 mutations are
associated with high-degree instability involving mononu-
cleotide and dinucleotide (and other short tandem) repeats
[11]. The same is true for PMS2 mutations [12]. MSH6
mutations are associated with low-degree MSI with a
preferential involvement of mononucleotide repeats [13].
In tumors from MLH3 mutation carriers, mononucleotide
repeats may be less informative than dinucleotide and
tetranucleotide repeats [14] and phenotypes ranging from
MSI-high [14] to no MSI [15] have been reported.
Germline mutations in MMR genes predisposing
to LS
Shares of individual MMR genes
MLH1, MSH2, MSH6 and PMS2 account for 40, 34, 18,
and 8 %, respectively, of the 3000 unique germline
sequence variants of MMR genes deposited to the Inter-
national Society for Gastrointestinal Hereditary Tumours
(InSiGHT) database ([16] and www.insight-group.org, date
accessed December 19th, 2015). The different substrate
specificities described above may explain why MLH1 and
MSH2 are the most important predisposing genes for LS
(their protein products are obligatory components in all
types of heterodimers, Fig. 1), followed by MSH6 and
PMS2, whereas MLH3 mutations are rare (functionally
redundant with PMS2), and no LS-predisposing germline
mutations are known for MSH3 (functionally redundant
with MSH6). No LS-associated germline mutations have
been detected in MSH4 or MSH5 (their primary role is in
meiotic recombination rather than MMR).
Mutation spectra
Mutations are scattered throughout the MMR genes (www.
insight-group.org). Figure 2 displays the gene-specific
distributions of germline variants by the type of mutation
and predicted coding change [17]. Most MLH1, MSH2, and
MSH6 mutations are truncating (predominantly nonsense
or frameshift mutations). Moreover, the share of missense
changes, which lead to single amino acid substitutions, is
significant (*30–60 %) for all four genes. The abundance
of missense mutations prompted the InSiGHT to undertake
a large-scale effort to classify MMR gene variants
according to pathogenicity, based on variant and family
characteristics on the one hand and results from various
functional assays on the other hand [16]. A five-tiered
classification of the International Agency for Research on
Cancer was adopted since it is linked to clinical
Fig. 1 The different hMutS and
hMutL complexes in human
MMR. In addition to MMR
proteins, the repair process
requires a number of other
proteins, such as proliferating
cell nuclear antigen (PCNA),
replication factor C (RFC),
EXO1 (a 50–30 exonuclease),
DNA helicases, RPA
(replication protein A, a single-
stranded DNA binding protein),




recommendations. Classes 5 and 4 indicate a ‘‘pathogenic’’
and ‘‘likely pathogenic’’ variant, respectively, implying
that a causative mutation was detected that warrants
surveillance according to full high-risk guidelines and
qualifies for predictive testing of at-risk relatives. Nonsense
and frameshift mutations constitute a majority (59 %) of
class 5 and 4 variants [16]. Classes 2 and 1 indicate a
‘‘likely non-pathogenic’’ and ‘‘non-pathogenic’’ variant,
respectively, suggesting that the test result was normal and
is to be treated as ‘‘no mutation detected’’. Intronic variants
(42 %) as well as non-synonymous (29 %) and synony-
mous (18 %) missense variants are the main types of
changes represented among class 2 and 1 variants [16].
Class 3 is synonymous with a variant of unknown signifi-
cance (VUS) that requires a multilevel functional assess-
ment for a reliable assignment of pathogenic significance
and clinical treatment is case by case. Non-synonymous
missense changes are abundant (68 %) among class 3
variants [16]. Figure 3 shows the breakdown of the main
pathogenicity classes across each MMR gene, based on the
germline mutation data deposited in the InSiGHT mutation
database [16]. Pathogenic mutations (classes 4 ? 5) con-
stitute a majority (except for MSH6 with a dominant class
3) and normal variants (classes 1 ? 2) constitute a
minority of all database variants for each gene. The share
of VUSes is 31 % for all deposited variants inMLH1, 28 %
for MSH2, 47 % for MSH6, and 26 % for PMS2.
Unique versus recurrent mutations
Most MMR gene mutations are inherited from either parent
and de novo mutations are rare (2.3 % [18]). A majority of
all MMR gene mutations are unique, i.e. specific to a single
family. However, some prevalent recurrent mutations are
known and based on haplotype analysis, may arise de novo
or alternatively, represent founder mutations [19]. Certain
regions of MMR genes may be mutation-prone due to
specific sequence characteristics. For example,
c.942?3A[T, a splicing mutation in intron 5 of MSH2 and
one of the most frequently recurring MMR gene mutations
worldwide, is likely to arise as a consequence of
misalignment while replicating 26 consecutive adenines, of
which the mutation-associated adenine is the first [20]. The
same A26 repeat is part of BAT26, a key marker in MSI
detection [21]. The c.942?3A[T mutation arises de novo
in some populations [20] and represents a founder mutation
in other populations [22]. Founder mutations originate
from a single ancestor and become enriched in isolated
populations [23]. Based on the extent of haplotype con-
servation, the age of founder mutations in MMR genes
ranges from a few hundred to more than a thousand years
Fig. 2 Distributions of the
types of germline variants
across each MMR gene. The
analysis is based on data
deposited in the InSiGHT
database [17] and is restricted to
variants with coding changes.
The total numbers of variants
per gene included in the analysis
are 1104 for MLH1, 883 for
MSH2, 414 for MSH6, and 197
for PMS2
Fig. 3 Distributions of the different pathogenicity classes within the
LS-associated MMR genes. The relative shares of normal variants
(pathogenicity classes 1 and 2), VUSes (class 3), and pathogenic
mutations (classes 4 and 5) reported for each MMR gene in the
InSiGHT database [16] are depicted. The analysis includes 932
sequence variants for MLH1, 842 for MSH2, 449 for MSH6, and 137
for PMS2
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[19]. To date, over 50 proven founder mutations in MMR
genes are known from all over the world and may account
for over 50 % of all LS families in some populations [19].
Rates of mutation detection in LS families
Germline mutations in MMR genes are detectable in up to
88 % of LS families fulfilling the Amsterdam criteria [24,
25] and showing MSI in tumors [26, 27]. Smaller or
atypical families and families not pre-screened for MMR
deficiency in tumor tissues may display mutation fre-
quencies of 10–40 % depending on the criteria of ascer-
tainment [26, 28, 29]. A genetic point mutation is the
predominant type of germline mutation in MMR genes in
most populations [26, 27, 30]. Analysis of LS cohorts from
several different geographic locations yielded a frequency
of 15 % (68 unrelated kindreds out of 439) for large
genomic rearrangements; among 48 different rearrange-
ments, 29 affected MSH2, 13 MLH1, 2 MSH6 and 4 PMS2
[31]. A few percent of Lynch-suspected families with
MMR-deficient tumors and negative for point mutations
and large rearrangements are due to constitutional epimu-
tations in MMR genes (see below).
Over half of MMR-deficient tumors that are not
explained by germline mutations or (acquired or constitu-
tional) promoter methylation of MMR genes (‘‘Lynch-like
syndrome’’) were recently shown to arise as a consequence
of somatic mutations in MMR genes [32–34] occasionally
combined with POLE/POLD1 defects [35], i.e. are non-
hereditary as a rule. MMR gene mutations are very rare in
families with MMR-proficient tumors, even if they meet the
Amsterdam criteria (Familial Colorectal Cancer Type X)
[36]. The genetic basis of Familial Colorectal Cancer Type
X families seems heterogeneous and predisposing genes and
mutations remain unknown in a majority [37–39].
Constitutional epimutations in LS predisposition
Constitutional epimutation refers to hypermethylation at
the promoter of one allele of a given gene leading to
silencing of expression from that allele in all main somatic
tissues. Constitutional epimutation of MLH1 occurs in
2–3 % of mutation-negative Lynch-suspected families with
silenced MLH1 expression in tumors [40–42]. Since con-
stitutional epimutations are reversible during meiosis [43],
epimutations segregate in a non-Mendelian fashion and are
seldom associated with strong family histories of cancer.
Epimutations secondary to genetic mutations constitute an
exception and may arise on ancestral founding haplotypes
[44]. The prevalence of MLH1 constitutional epimutations
in colorectal cancers lacking MLH1 expression and
showingMLH1 methylation in tumor tissue was reported to
be 0 % among unselected cases and 16 % among cases
fulfilling the revised Bethesda criteria [21], suggesting that
testing for MLH1 epimutations should regularly be
restricted to the latter group of patients [45].
Constitutional epimutations of MSH2 are secondary to
deletions of the 30 end of the EPCAM gene which make
transcription of EPCAM read into the adjacent, structurally
normal MSH2 gene inducing its promoter to be methylated
[46]. EPCAM deletion-associated MSH2 epimutations vary
a lot in frequency between populations depending on
possible founder effects and may account for 10–40 % of
families with absent MSH2 protein in tumors [42, 46].
Such epimutations show regular Mendelian transmission
along with EPCAM deletion in pedigrees [46].
Genotype–phenotype correlations
Cancer risks associated with germline mutations
in individual MMR genes
The lifetime risks of cancer are significantly higher in
MSH2 and MLH1 mutation carriers compared to carriers of
MSH6 or PMS2 mutations, which may reflect functional
redundancy of MSH6 (with MSH3) and PMS2 (with
MLH3 and PMS1) (see above). The lifetime risk by age 70
of any LS-associated cancer has been found to range
between 57 % [47] and close to 80 % [48] for MSH2 and
59 % [47] and*65 % [48] for MLH1. For MSH6, lifetime
risks of 25 % for males and females combined [47] and
24 % (males) and 40 % (females) [49] have been reported.
Heterozygous PMS2 mutation carriers may have a
25–32 % lifetime risk of any cancer [50].
Among the various cancers arising in MSH2 and MLH1
mutation carriers, the highest lifetime risk is for colorectal
cancer, followed by endometrial cancer and other extra-
colonic cancers; moreover, MSH2 mutations may be
associated with higher risks of extracolonic cancers com-
pared to MLH1 mutations [48, 51]. Female carriers of
MSH6 mutations are at a higher risk of endometrial than
colorectal cancer [47, 49, 52]. The same may be true for
heterozygous carriers of PMS2 mutations [50]. Further-
more, MSH6 and PMS2 mutations show reduced age-
specific penetrance, resulting in higher average ages at
onset of various cancers in MSH6 [52] and PMS2 [50, 53]
carriers compared to MSH2 or MLH1 mutation carriers,
although family- and/or mutation-specific variations exist.
No clear-cut correlations have been observed between the
type (e.g., truncating vs. missense) or location (e.g., rela-
tive to different functional domains) of a MMR gene




A major puzzle in LS (in common with a majority of
familial cancer syndromes) is the specific spectrum of
tumors in constitutional mutation carriers. The Amsterdam
II criteria [25] acknowledge cancers of the colon and rec-
tum, endometrium, small bowel, ureter, and renal pelvis as
LS-associated cancers, based on their significant overrep-
resentation in LS compared to the average population.
Since these criteria were formulated, significantly
increased standardized incidence ratios have repeatedly
been reported for several other cancers as well, including
cancers of the stomach, ovaries, and pancreas [54, 55].
Combined with molecular profiles characteristic of LS
(e.g., consistent MMR protein loss or MSI [56–58],
inclusion of these tumors in the LS spectrum seems justi-
fied. For breast cancer, the observed standardized incidence
ratios vary from comparable to the average population [59,
60] to significantly elevated [54, 55], making it difficult to
conclude whether or not breast cancer belongs to the LS
spectrum. A recent comparative study on proven mutation
carriers versus non-carriers did find a significant difference
in the rate of MMR deficient breast carcinomas between
those two groups (65 vs. 0 %, P\ 0.001) [61]. Moreover,
the age at onset in mutation carriers depended on the MMR
status of their tumors (earlier onset if the tumor was MMR-
deficient), suggesting a role for deficient MMR in breast
cancer development in LS [61].
Factors that may contribute to the LS tumor
spectrum
As described above, the individual MMR genes may be
associated with somewhat different tumor spectra. In
addition, a number of other factors may contribute to the
LS tumor spectrum. Tissue-specific patterns of MMR
deficiency in cancers from MMR gene mutation carriers
(Fig. 4) may constitute one such factor. While immuno-
histochemical analysis of malignant tumors regularly
demonstrates the absence of MMR protein corresponding
to the gene mutant in the germline, the frequencies of
tumors with MSI-high vary, being 80 % or above for
stomach, ovary, colon, and ureter cancer, *50 % for
bladder, endometrium, and kidney cancer, and 35 % or
below for breast and brain tumors [57, 61, 62]. Clonal
heterogeneity is a feature of LS and sporadic MMR-defi-
cient tumors [63, 64] and may in part explain the different
frequencies of MSI between tumor types. Moreover, BAT
markers show shorter allelic shifts in endometrial cancers
compared to colorectal cancers from LS patients [65]. Such
differences may be important considering the fact that
genes with repetitive sequences in coding regions are
mutation-prone in MMR-deficient cancers. Different genes
confer selective advantage in different cancers, for exam-
ple, the TGFb superfamily is a mutational target in gas-
trointestinal cancers and PTEN in endometrial cancers [65,
66]. Tissue-specificity for MMR deficiency and genes tar-
geted by failing MMR may therefore contribute to organ-
selectivity.
Two lines of evidence imply that the dosage of the
MMR gene or protein is important for phenotype. First,
homozygosity or compound heterozygosity for germline
mutation gives rise to a distinct syndrome, constitutional
mismatch repair deficiency syndrome (CMMRD). Cur-
rently, 146 patients from 91 families with this syndrome
are known [67]. Childhood cancers of the hematological
system and brain, signs of neurofibromatosis type 1 (cafe´-
au-lait spots) and Turcot syndrome (coexistence of col-
orectal tumor and brain tumor) are common manifestations
of CMMRD. The peculiar tumor spectrum may reflect the
sensitivity of particular (e.g. neural and hematological)
progenitor cells to MMR deficiency via specific somatic
target genes (NF1 mutation [68]). PMS2 and MSH6 pre-
dominate over MSH2 and MLH1 as genes underlying
CMMRD [67]. Contrary to traditional LS with heterozy-
gous MMR gene mutations, CMMRD patients lack
expression of the MMR protein(s) in question not only in
cancer tissue but in normal tissue as well. MSI in tumor
tissues varies in the same way as in conventional LS
(present in gastrointestinal tumors but absent in brain
tumors as shown for LS in Fig. 4). Standard techniques
cannot usually detect MSI in peripheral blood lymphocytes
because of clonal heterogeneity, whereas immortalized
lymphoblastoid cells may reveal a MSI phenotype [67].
Another line of evidence in support of the importance of
MMR gene or protein dosage comes from observations that
the presence of the wild-type copy of a MMR gene in
somatic cells is not always sufficient for a normal function
(haploinsufficiency). While MMR genes usually comply
Fig. 4 Tumor-specific patterns of MMR defects. Percentages of
tumors with MSI-high and MMR protein inactivation among cancers
arising in different organs in germline carriers of MMR gene
mutations from a nation-wide registry [57, 61, 62] are shown
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with Knudson’s two-hit hypothesis for tumor suppressor
genes [69] as evidenced by the lack of the responsible
MMR protein in LS-associated cancers (biallelic inactiva-
tion), colorectal adenoma development seems possible in
LS even if the wild-type allele of the predisposing MMR
gene is retained [70, 71]. Other possible molecular ‘‘hits’’,
such as epigenetic inactivation of tumor suppressor genes
[71] may contribute to tumor initiation in such haploin-
sufficient cells. Haploinsufficiency may be function-
specific; for example, it has been demonstrated that DNA
damage signaling requires a higher dosage of MMR protein
than the repair function [72]. Failure of apoptosis signaling
likely provides MMR-deficient cells with selective advan-
tage needed for tumorigenesis [73]. Different organs may
have different requirements for MMR gene dosage [61,
74], which may influence their susceptibility to tumor
development.
As discussed above, the MMR system recognizes sev-
eral other types of DNA damage besides replication errors,
including oxidative [3] and alkylating [4] damage, as well
as heterocyclic amine (e.g., PhIP) DNA adducts [75]. Such
damage can be exogenous (e.g., PhIP is a cooked meat-
derived mutagen [75]) or endogenous (e.g., oxidation
resulting from normal cellular metabolism or inflammation
[76]). Organs commonly exposed to such damage, such as
the gastrointestinal tract and endometrial epithelium,
would obviously be at elevated risk of cancer development,
especially in individuals with deficient MMR. Unhealthy
diet (‘‘snack’’ pattern [77] and tobacco smoking [78] have
been shown to increase colorectal adenoma risk in MMR
gene mutation carriers, which might imply a reduced
capacity to correct dietary and tobacco-associated damage.
Tumor development initiated by replication errors or
carcinogen-induced mutations may proceed at different
rates in different tissues depending on their proliferative
activity [79]. Colon and many other epithelial cells have
fast turnovers, and there may be less time to repair repli-
cation errors if cell cycles are short [80]. Furthermore, in
colon and other epithelial organs, stem cell divisions con-
tinue throughout life. Hematopoietic tissue, too, is highly
proliferative, but may be less prone to malignancies
because of fewer stem cell divisions during lifetime [80].
These general concepts are in agreement with the fact that
a majority of LS-associated tumors are epithelial and that
MMR deficiency also predisposes to hematological
malignancies, but mainly in the context of CMMRD only.
Frameshift mutations typical of MMR deficiency result
in the formation of neoantigens recognized by the immune
system. Consequently, colon, gynecological, and other
tumors from LS patients display high levels of tumor
infiltrating lymphocytes (TILs) [81, 82]. The abundance of
CD8? cells (dominant in TILs) is a good prognostic sign in
LS and sporadic cancers [81, 83]. On the other hand,
frameshift mutations may also affect cell surface proteins
responsible for antigen processing and presentation and
thereby facilitate escape from immune surveillance [84].
Varying frequencies of MMR defects in different types of
tumors (Fig. 4), combined with possible variations in the
inherent efficacy of immune surveillance in different
organs, may thus contribute to organ-specific tumor sus-
ceptibility in LS.
Concluding remarks
Research on LS conducted to date has greatly advanced our
understanding of the significance of the MMR system in
human cancer. Yet, many essential questions wait for
definitive answers regarding the mechanisms of tumorige-
nesis (e.g., two-hit inactivation vs. haploinsufficiency) and
the complex relationship between genotype and phenotype
(e.g., genetic vs. non-genetic influences; unequivocal def-
inition of the LS tumor spectrum) to mention a few. Tar-
geted gene panels based on next-generation sequencing
[85, 86] will be changing the approach to screen for pre-
disposing mutations in LS and other hereditary disorders in
the coming years. The simultaneous screening of all LS-
associated MMR genes and other possible susceptibility
genes in LS-suspected cases is likely to more accurately
define the spectrum of genes and mutations predisposing to
LS and the population incidence of LS. Next-generation
sequencing of the whole exomes and genomes is also
anticipated to provide new insights into the genetic basis of
colon cancer families that are unrelated to MMR defects
(Familial Colorectal Cancer Type X) [38, 87, 88].
Comprehensive genetic, epigenetic, and expressional
cataloguing of tumor alterations in analogy to ongoing
efforts on sporadic cancers (e.g., by the Cancer Genome
Atlas Network [89, 90]) will be useful to define the
developmental mechanisms of colonic and extracolonic
tumors in LS and to better understand the molecular basis
of organ-specific tumor susceptibility. Targeted studies [57,
91] have already revealed distinct mutational patterns in LS
tumors that may explain the disease outcome and be clin-
ically actionable. When linked to clinical parameters,
comprehensive molecular profiles of constitutional and
tumor tissues will be informative to establish clinical cor-
relations of molecular aberrations and facilitate the man-
agement of individuals with LS.
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